Short answer
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 2.05 (Costs Associated with Exit or Disposal Activities). Press release announces Mark Van Oene’s appointment as PacBio chief executive officer.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Mark Van Oene’s appointment as PacBio chief executive officer
- Leadership change may affect strategy, execution priorities, and investor expectations
- Exhibit 99.2 contains the substantive appointment details disclosed by the company
Item 2.05 · Costs Associated with Exit or Disposal Activities
- Workforce reduction of approximately 40 employees, or 8% of total workforce
- Annualized operating expense reduction targeted at $30 million–$40 million by end-2027
- Approximately $2.0 million pre-tax restructuring charges, primarily severance and related costs
- Reduction in force and charges expected to occur in Q3 2026
- Cost actions signal tighter resource allocation around strategic priorities
Item 5.02 · Departure/Election of Directors or Officers
- Mark Van Oene becomes CEO and director August 5, succeeding Christian Henry, who remains on the Board
- CEO compensation: $743,000 salary, 100% target bonus, $1.6875M option, and $562,500 RSU award
- Change-in-control severance expanded to 18 months’ salary and COBRA coverage from 12 months
- Henry receives $1,161,685.50 separation payment, salary through December 31, and continued equity vesting
- Leadership transition creates near-term cash and equity costs while preserving Henry’s Board involvement
Item 7.01 · Regulation FD Disclosure
- August 5, 2026 press release disclosed leadership changes at Pacific Biosciences
- Leadership transition may affect strategic execution and investor confidence
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $39.0M, down from $39.8M; consumables rose to $20.1M while instrument revenue declined to $12.8M
- Revio placements increased to 20 from 15, but Vega placements fell to 26 from 38 and annualized Revio pull-through declined to ~$202,000
- Non-GAAP gross margin fell to 36% from 38%, pressured by compute and memory costs, Vega transition costs, and lower Revio pricing
- Cash and investments declined to $236.9M from $314.7M at year-end, highlighting funding risk amid a $44.7M GAAP quarterly net loss
- 2026 revenue guidance remains $155M-$165M, with SPRQ-Nx rollout and Basecamp Research execution key commercialization catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K filings
Get the next PACB 8-K as it lands
Follow PACB for push alerts, or ask the research agent what this filing means.